NitroMed BiDil Launch Projected For 2005 Following Positive Study Results
This article was originally published in Pharmaceutical Approvals Monthly
NitroMed is counting on a compliance benefit to get BiDil on formularies if the combination product is approved for treatment of congestive heart failure in African American patients.
You may also be interested in...
NitroMed BiDil could be first drug cleared specifically for African Americans. Company plans NDA resubmission by year-end with results from African American Heart Failure Trial in response to 2001 "approvable" letter. A-HeFT data show 43% survival improvement vs. placebo. NitroMed targets launch for first-quarter 2005
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011